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This review investigated the relative performance of digital breast tomosynthesis (DBT) (alone or with
full ﬁeld digital mammography (FFDM) or synthetic digital mammography) compared with FFDM alone
for detecting breast cancer lesions in asymptomatic women. A systematic review was carried out ac-
cording to systematic reviewing principles provided in the Cochrane Handbook for Systematic Reviews of
Diagnostic Test Accuracy. A protocol was developed a priori. The review was registered with PROSPERO
(number CRD42014013949). Searches were undertaken in October 2014. Following selection, ﬁve studies
were eligible. Higher cancer detection rates were observed when comparing DBT þ FFDM with FFDM in
two European studies: the summary difference per 1000 screens was 2.43 (95% CI: 1.8 to 3.1). Both
European studies found lower false positive rates for individual readers. One found a lower recall rate
based on conditional recall. The second study was not designed to compare post-arbitration recall rates
between FFDM and DBT þ FFDM. One European study presented data on interval cancer rates; sensitivity
and speciﬁcity for DBT þ FFDM were both higher compared to FFDM. One large multicentre US study
showed a higher cancer detection rate for DBT þ FFDM, while two smaller US studies did not ﬁnd sta-
tistically signiﬁcant differences. Reductions in recall and false positive rates were observed in the US
studies in favour of DBT þ FFDM. In comparison to FFDM, DBT, as an adjunct to FFDM, has a higher cancer
detection rate, increasing the effectiveness of breast cancer screening. Additional beneﬁts of DBT may
also include reduced recalls and, consequently, reduced costs and distress caused to women who would
have been recalled.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Breast cancer is a signiﬁcant cause of mortality and morbidity
for women worldwide and is the most common cancer diagnosed
in women, with an estimated 1.67 million new cases diagnosed
worldwide in 2012 [1]. The incidence of breast cancer is highest in
developed countries with an age-adjusted incidence rate of 80 per
100,000 in the European Union and 92 per 100,000 in North
America [2], and it is the second most common cause of cancer
death in women in developed countries [2,3].
Screening with mammography can assist in detecting breast
cancer at earlier stages, which is associated with reductions in
mortality [4,5]. A recent systematic review of screening programme
studies found that the screening reduced mortality from breast
cancer for women invited to screening by approximately 23% and
for regular participants by approximately 40% [6].
Over the last decade, the majority of screening programmes
have changed from two dimensional (2D) analogue mammography
to full ﬁeld digital mammography (FFDM). Digital mammography
(DM) is associated with small increases in detection rates and re-
ductions in the number of false positives and is therefore likely to
increase the effectiveness of screening programmes [7,8]. It repre-
sents the current standard for most mammography programmes
and is the comparator in this review.
Description of the intervention
Digital breast tomosynthesis (DBT) (or three-dimensional (3D)
mammography) is a development of FFDM providing analysis of 3D
mammographic data through a series of tomographic image slices
through the breast allowing reconstruction in thin slices. This
provides greater detail and addresses the challenges of overlapping
tissue, which both obscures and mimics cancer. Both DBT and
mammography can be performed in one or two views.
DBT can also be used as an adjunct to FFDM: this requires a
second radiation exposure, increasing the dosage required for
FFDM. A DBT dataset can also be used to generate so-called syn-
thetic 2D images, avoiding the need for additional radiation expo-
sure. When DBT generates synthetic 2D images, the total patient
radiation exposure is similar to or slightly higher than FFDM [9].
The aim of this systematic review was to examine the performance
of DBT for breast cancer-screening.
Rationale
Published systematic reviews have assessed the use of DBT for the
detection and diagnosis of breast cancer. Lei et al. [10] examined the
relative performance of DBT þ FFDM compared to FFDM in womenwith mammographically evident breast lesions. They concluded that
one view DBT þ FFDM has higher sensitivity and speciﬁcity than
FFDM. This meta-analysis was limited by search criteria which
resulted in the inclusion of relatively small studies (the largest study
included 738 patients) with a high degree of variation in design.
Houssami et al. [11,12] considered the relative performance of
DBTþ FFDMandFFDMindetectingbreast cancer. Although studies in
theHoussami reviewdemonstrated increases in cancerdetection rate
using DBT þ FFDM over FFDM, its conclusions regarding screening
were qualiﬁed due to the test setting, small numbers and inclusion of
diagnostic cases with a high prevalence of cancers. Additionally, the
ﬁnal search date for this review was October 2012, prior to the pub-
lication of several major tomosynthesis screening trials. A 2015
editorial by Houssami [12] summarizes several recent screening
studies, but this review was not performed systematically and may
not be comprehensive. Further studies and reviews are required.
While there is evidence suggesting that DBT shows superior
performance diagnosing breast cancer, the relative performance of
DBT and FFDM for detecting cancer in an asymptomatic, screening
population has not been fully explored and researchers have sug-
gested that this should be assessed by a variety of methods
including a current review [11].Review question
What is the performance of DBT (alone or in combination with
FFDM or synthetic DM) for detecting breast cancer compared with
FFDM alone when screening asymptomatic women?Methods
This systematic review was carried out according to the sys-
tematic review guidance provided in the Cochrane Handbooks
[13,14]. A protocol was developed a priori and was registered with
PROSPERO (CRD42014013949) on 29 September 2014. The searches
were performed and concluded in October 2014.Eligibility criteria
Prospective studies or retrospective studies with 1000þ par-
ticipants, evaluating the following comparisons were eligible for
the systematic review:
 FFDM alone compared to DBT alone;
 FFDM alone compared to DBT þ FFDM;
 FFDM alone compared to DBT þ DBT-generated 2D images.
R. Hodgson et al. / The Breast 27 (2016) 52e6154Studies were required to have been performed on systems
possessing a CE mark or US Food and Drug Administration (FDA)
approval.
Studies were eligible for inclusion in the review if they eval-
uated women participating in a breast cancer screening pro-
gramme or who were undergoing opportunistic mammography
screening.
Studies evaluating women meeting any of the following criteria
were excluded:
 Having a previous diagnosis of and treatment for breast cancer;
 Presenting with symptoms of breast cancer or having been
referred for examination (because of the detection of a possible
lump);
 Having been recalled for diagnosis or further testing following a
screening mammogram.
Studies were also ineligible if they met any of the following
criteria:
 Compared DBT with (2D) analogue/ﬁlm mammography;
 Evaluated DBT systems for the purpose of technological
development;
 Reported results in languages other than English;
 Were reported only as conference abstracts;
 Were conducted before 2008 (before 2008 no system had a CE
mark or FDA approval).Reference standard
The reference standard for the positive cases of cancer was
histological results conﬁrmed by biopsy or surgical resection.Records identified through 
database searching 
(n = 10,002) 
Addi
Records after duplicates re
(n = 5,759 ) 
Records screened
(n = 5759 ) 
Full-text articles asses
for eligibility 
(n = 94 ) 
Eligible reports 
(studies=5; reports = 1
Fig. 1. Study selecThe reference standard for the negative cases was any follow-up
period, where reported. The follow-up period is important to
determine whether any recall rate reduction leads to an increase in
missed cancers over time. However, if follow-up was not reported,
studies were still eligible, although such studies did not provide
information regarding absolute sensitivity.Search strategy, selection and data extraction
Sensitive searches were conducted in relevant international
databases of published research (full details are provided in the
Supplementary Appendix) up to October 2014. Reference lists of
relevant papers retrieved by the searches were scanned for
potentially eligible studies. Systematic reviews identiﬁed by the
searches were checked for additional reported research not
retrieved by the database searches. Citation searches were carried
out on identiﬁed records.
Before proceeding to formal record selection, irrelevant records
(animal studies, conference abstracts and editorials) were removed
by an experienced information specialist. Two reviewers (JG, JS)
independently selected records using information in the title and
abstract. Records which were of unclear relevance were retained.
The full documents of all potentially relevant studies were obtained
and were assessed for relevance by one reviewer and checked by a
second reviewer. Disagreements on relevance were resolved
through discussion or consulting a third reviewer. Studies consid-
ered ineligible, based on an assessment of the full document, are
listed in the Supplementary Appendix.
As recommended by the Cochrane Handbook for Systematic
Reviews of Diagnostic Test Accuracy [13], the risk of bias of studies
was assessed by two reviewers independently using 11 of the 14
mandatory items in the QUADAS-2 tool [15,16].tional records identified through 
other sources 
(n = 14 ) 
moved 
 Records excluded 
(n = 5,665 ) 
sed Full-text articles excluded 
(n = 78 ) 
6 ) 
tion process.
Table 1
Summary of study characteristics.
Study name Country Study design Index test and
manufacturer
Comparator test and
manufacturer
Age Inclusion criteria/
Exclusion criteria
Reference standard Double or
single reader
STORM
(Ciatto
2013)
Italy Prospective,
fully paired
design
Integrated 2D and
3D mammography;
Hologic e Selenia
Dimensions
2D mammography; Hologic Median age: 58 years
(IQR 54e63, range 48e71)
Women aged > 48
years attending a
population-based
breast cancer
screening
programme.
Participants were
asymptomatic
women at standard
(population) risk
for breast cancer.
Excision histology
for those patients
who received
surgery and
complete outcome
assessment with
and without needle
biopsy in those who
did not receive
surgery.
Double reader
STORM
(Houssami
2014)
Italy Prospective,
fully paired
design
Integrated 2D and
3D mammography;
Hologic e Selenia
Dimensions
2D mammography; Hologic Median age: 58 years Women
aged 48 years
Women aged > 48
years attending a
population-based
breast cancer
screening
programme.
Participants were
asymptomatic
women at standard
(population) risk
for breast cancer.
Excision histology
for those patients
who received
surgery and
complete outcome
assessment with
and without needle
biopsy in those who
did not receive
surgery.
Single and
retrospective
double reading
algorithm
Destounis
2014
US Retrospective
review
Integrated 2D and
3D mammography;
Hologic e Selenia
Dimensions
2D mammography; Three
manufacturers:
1. Selenia/Dimensions, Hologic;
2. Senographe Essential, GE;
3. Fuji CRm, FUJIFILM
1. Average age FFDM only group:
59 years (range: 30e90 years) 2.
Average age DBT þ FFDM group:
59 years (range: 36e92 years)
Women aged > 30
years attending a
New York
screening
mammography
centre.
Biopsy Double reader
Friedewald
2014
US Retrospective
review
Integrated 2D and
3D mammography;
Hologic e Selenia
Dimensions
2D mammography; Hologic 1. Average age for digital
mammography alone: 57 years
(range of means from 13 sites,
54.4e60.5 years) 2. Average age
for digital
mammography þ tomosynthesis:
56.2 years (range, 52.6e59.7
years)
Women were
enrolled from 13
different radiology
sites in the US.
Biopsy Single reader
Lourenco
2014
US Retrospective
review
2D mammography;
GE Medical and 3D
mammography
Hologic e Selenia
Dimensions
2D mammography; GE Medical 1. Average age for DM: 54.6
years ± 10.7 (range, 29.4e90.6
years) 2. Average age for DBT:
55.3 years ± 10.8 (range, 30.9
e89.4 years)
NR Biopsy Single reader
OTST
(Skaane
2013A)
Norway Prospective,
fully paired
design
Integrated 2D and
3D mammography;
Hologic e Selenia
Dimensions
Integrated Age range: 50e69 years Women (aged 50
e69 years) who
participated in the
biennial Oslo breast
cancer screening
programme.
Potential
candidates were
selected on the
basis of the
availability of
appropriate staff.
Biopsy Single reader
(continued on next page)
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R. Hodgson et al. / The Breast 27 (2016) 52e6156Details of eligible studies were extracted and summarised using
an Excel data extraction template. Data were extracted by one
reviewer and checked by a second reviewer.
Discrepancies between reviewers were resolved through dis-
cussion or by consulting a third reviewer.
Data analysis
Analysis was conducted using Stata 12.0 and performed in
compliance with the methods and techniques described in the
Cochrane Handbook for Systematic Reviews of Diagnostic Test Ac-
curacy [13]. Fixed effect analysis was carried out where statistical
heterogeneity was low and the random effects model was used
where moderate heterogeneity was observed. Where high het-
erogeneity was observed, a combined summary estimate was not
performed and a narrative exploration of differences was
conducted.
It was pre-planned to investigate publication bias using funnel
plots if ten or more studies were identiﬁed. However, the small
number of studies identiﬁed meant that this was not possible.
Results
Search results
Study selection is presented in Fig. 1. 10,016 records were
identiﬁed from the searches and after removing duplicates, 5759
records were assessed for relevance. The full documents of 94
potentially eligible studies were obtained and ﬁve studies (reported
in 16 documents) met the review eligibility criteria. The documents
excluded based on the full text are listed in the Supplementary
Appendix.
Characteristics of the included studies
Table 1 summarises the characteristics of the eligible studies.
Two studies were conducted in Europe; the Oslo Tomosynthesis
Screening Trial (OTST) [9,17,18] was conducted in Oslo, Norway and
the STORM study [19e22] was carried out in Italy. The other three
studies (Destounis 2014 [23], Lourenco 2014 [24] and Friedewald
2014 [25e31]) were conducted in the US. The largest study, Frie-
dewald 2014 [26], was a multicentre study that enrolled women at
13 centres.
OTST [9,17,18] and STORM [19e22], were undertaken within
population-based biannual mammography screening programmes.
They used a prospective fully paired design in which screened
womenwere invited consecutively to participate and undergo two-
view FFDM and two-view DBT. Both used an independent double
reader process, although the processes used to decide which
women to recall were different. In the OTST study [9,17,18]
consensus double reading was undertaken of slightly different
data sets. The study had four reading arms and to generate double
reading data the readings from the FFDM alone reading arm was
combined with the FFDM and computer aided detection (CAD)
reading arm, and for the combination mode, the results of the
FFDM and DBTarmwere combined with the results of the synthetic
2D mammography and DBT reading arm. The blinded in-
terpretations were entered into the screening database. Cases with
a positive interpretation by either reader were presented to a single
consensus group of readers who had access to all the imaging in-
formation (FFDM and DBT) to inform their decision about whether
to recall the patient. In the STORM study [19e22], women were
recalled if either reader recorded a positive screen, so no process of
arbitration was used in the decision to recall. The comparison of
recall and false positive rates reported is therefore a retrospective
Table 2
Summary of QUADAS-2 risk of bias assessment.
Table 3
DBT þ FFDM vs. FFDM: Sensitivity and Speciﬁcity based on 1 year follow-up of STORM.
DBT þ FFDM FFDM
Cancer detected
at screening
Missed cancers þ interval
cancers
Sensitivity Speciﬁcity Cancer detected
at screening
Missed cancers þ
interval cancers
Sensitivity Speciﬁcity
59 6 90.77% CI
(80.7%e to 96.51%)
96.49% CI
(96.04% to 96.90%)
39 26 60.00% CI:
(47.10% to 71.96%)
95.55% CI
(95.04% to 96.01%)
R. Hodgson et al. / The Breast 27 (2016) 52e61 57conditional rate, rather than (as is typical in Europe) a double
reading strategy using arbitration.
The OTST study [9,17,18] had four reading arms. Arm 1 used
FFDM alone, arm 2 used FFDM plus computer aided diagnosis, arm
3 used DBTþ FFDM, and arm 4 used DM synthetically-generated by
DBT. The results of the study were presented in three manuscripts.Table 4
DBT þ FFDM versus FFDM: false positives, recall rate, cancer detection rate, invasive can
Study DBT þ FFDM
False positives Recall rate Cancer
detection
rate
Invasive c
detection
European studies
STORM 254/7294a
(3.5%)
313/7294a (4.3%) 59/7294
(0.81%)
52/7294
(0.71%)
OTST single
reading
670/12,621b
(5.31%)
351/12,621b
(2.78%)
101/12,621
(0.80%)
81/12,621
(0.64%)
OTST double
reading
1057/12,621b
(8.5%)
463/12,621b
(3.67%)
119/12,621
(0.94%)
94/12,621
(0.74%)
US studies
Destounis 2014 19/524
(3.63%)
22/524 (4.20%) 3/524 (0.57%) 1/524 (0.1
Lourenco 2014 767/12,921
(5.94%)
827/12,921 (6.40%) 60/12,921
(0.46%)
30/12,921
(0.23%)
Friedewald 2014 14,591/173,663
(8.40%)
15,541/173,663
(8.95%)
950/173,663
(0.55%)
707/173,6
(0.41%)
a False positives and recalls for the DBT þ FFDM arm of the STORM trial were calculate
were positive based on FFDM, but not DBT, would not be recalled).
b False positives for the OTST were calculated as the number of participants without a
cases sent for further evaluation after arbitration, during which FFDM and DBT informatio
alone).One report [18] compared a single read of FFDM with a single
reading of DBT þ FFDM and a second [17] reported the same
comparison using double reading. A third report [9] presented re-
sults of DBT þ FFDM versus DBT þ synthetically-generated DM.
STORM was reported in multiple manuscripts [19e22]. Ciatto
et al. [21] presented results for cancer detection rates and falsecer detection rates.
FFDM
ancer
rate
False positives Recall rate Cancer
detection
rate
Invasive cancer
detection rate
322/7294 (4.4%) 362/7294
(5.0%)
39/7294
(0.53%)
35/7294
(0.48%)
771/12,621b
(6.11%)
265/12,621b
(2.1%)
77/12,621
(0.61%)
56/12,621
(0.44%)
1286/12,621b
(10.3%)
365/12,621b
(2.9%)
90/12,621
(0.71%)
67/12,621
(0.53%)
9%) 58/524 (11.07%) 60/524
(11.45%)
2/524 (0.38%) 1/524 (0.19%)
1107/12,577
(8.80%)
1175/12,577
(9.3%)
68/12,577
(0.54%)
41/12,577
(0.33%)
63 28,519/281,187
(10.14%)
29,726/281,187
(10.57%)
1207/281,187
(0.43%)
815/281,187
(0.29%)
d using positive integrated DBT and FFDM as a condition to recall (i.e. exams which
veriﬁed cancer who were referred to arbitration. Recalls were determined based on
n was available for all cases (including those sent to arbitration based on FFDM data
Fig. 2. DBT þ FFDM vs. FFDM: cancer and invasive cancer detection rates per 1000 screens (European studies).
R. Hodgson et al. / The Breast 27 (2016) 52e6158positive rate and Houssami et al. [22] reported results for interval
cancer.
All of the US studies [23e31] were retrospective reviews in
which screened women received either FFDM, or DBT þ FFDM. The
US multicentre study was also reported in a number of additional
manuscripts. Most notable is Rose et al. [31] which reported a
paired analysis (DBT þ FFDM vs FFDM alone) of a subset of the
participants. In two of the US studies (Lourenco 2014 and Friede-
wald 2014 [25e31]) single reader design was used, with only one
radiologist reviewing the images (standard practice in the US). In
the third US study (Destounis 2014 [23]) double reading of
mammography images was performed.
Risk of bias in included studies
Four of the ﬁve eligible studies were rated to have low risk of
bias and one (Lourenco 2014 [24]) was rated to have unclear risk of
bias (Table 2). Studies were rated high risk of bias based on the
domain of partial veriﬁcation, because follow-up was applied only
to those patients recalled. Studies were also rated high risk of bias
based on blinding of the application of the reference standard. In all
cases this was due to the nature of the study design, as it is
impossible to blind readers to the type of mammography they are
reviewing. This was not considered to represent a signiﬁcant risk of
bias for the outcomes presented in the studies. Lourenco 2014 [24]
was rated to have unclear risk of bias on 8/11 of the criteria. All
three of the US studies used a retrospective observational design,
and this creates the potential for confounding bias, where observed
differences between screening methods are attributable to differ-
ences between groups. However, all of the studies were conducted
at the same sites, and patient groups werewell balanced in terms of
demographic factors.
Study results
The results of US and European studies were treated separately,
because of differences in breast cancer rates, demographics and
screening practices.
Results of the European studies
As there was only limited follow-up within the studies and
only one study (STORM [19e22]) presented interval cancers, it wasnot possible to assess programme sensitivity and speciﬁcity.
Table 3 presents estimated sensitivity and speciﬁcity based on the
limited follow up data reported in STORM [19e22]. DBT þ FFDM
has higher sensitivity than FFDM: 90.77% (95% CI: 80.70% to
96.51%) compared with 60.00% (95% CI: 47.10% to 71.96%).
DBT þ FFDM also had higher speciﬁcity than FFDM: 96.49% (95%
CI: 96.04% to 96.90%) compared with 95.55% (95% CI: 95.04% to
96.01%).
Table 4 presents cancer detection, false positive and recall rates
of the two European studies comparing DBT þ FFDMwith FFDM. In
both studies a higher cancer detection rate was observed using
DBT þ FFDM compared to FFDM.
A ﬁxed effect meta-analysis of the studies (Fig. 2) gives a highly
statistically signiﬁcant (p < 0.001) summary difference in the
cancer detection rate per 1000 screens of 2.43 (95% CI: 1.76 to 3.1)
for all cancers. Similarly, both studies observed a higher invasive
cancer detection rate, but did not report a statistically signiﬁcant
difference in non-invasive (in situ) cancer detection.
A ﬁxed effect meta-analysis of the studies (Fig. 2), also gives a
highly statistically signiﬁcant (p < 0.001) summary difference in
the invasive cancer detection rate per 1000 screens of 2.33 (95%
CI: 1.67 to 3.00). Results based on the single reader mode are
nearly identical to those using a double reader mode with fewer
false positives and recalls, and higher cancer detection using
DBT þ FFDM.
The two European studies observed quite different results
with respect to the false positive rate and the recall rate. In
STORM [19e22] lower false positive and recall rates were
observed when using DBT þ FFDM compared to FFDM. The dif-
ference per 1000 screens for false positives was 9.3 (95%
CI: 11.8 to 7.2) and for recall rate was 6.6 (95% CI: 8.7
to 4.9). In OTST [9,17,18] lower false positive rates using
FFDM þ DBT were found pre-arbitration, but higher false positive
and recall rates were found post-arbitration. The difference per
1000 screens for false positives in pre-arbitration was 8 for
FFDM þ DBT versus FFDM alone. After consensus by arbitration,
the difference for FFDM þ DBT versus FDFM was þ5.4 (95% CI:
4.2 to 6.8) for false positives per 1000 screens and þ6.2 (95% CI:
4.9 to 7.7) for recalls per 1000 screens. Attempts to combine the
results of these studies using meta-analysis resulted in signiﬁ-
cant heterogeneity: I2 ¼ 99% for the false positives and I2 ¼ 89%
for the recall rate. A summary effect was, therefore, not
calculated.
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Table 4 presents the results of the US studies. The large multi-
centre study, Friedewald 2014 [25e31] found a highly statistically
signiﬁcant difference per 1000 screens in favour of DBT þ FFDM
over FFDM: 1.21 (95% CI: 0.82 to 1.63). The small Destounis 2014
study [23] found a 1.91 difference (95% CI: 6.43 to 10.25; NS) in
favour of DBT þ FFDM and the small Lourenco 2014 study [24]
found a cancer detection rate difference of 0.76 (95% CI: 2.5 to
0.97; NS) favouring FFDM.
A statistically signiﬁcantly higher invasive cancer detection rate
in favour of DBTþ FFDMwas observed in the large Friedewald 2014
study [25e31]: the difference per 1000 screens was 1.20 (95% CI:
0.80 to 1.60). In the smaller studies, a lower rate (0.94 (95%
CI: 2.2 to 0.35)) in favour of DBT þ FFDM was found in Lourenco
2014 [24] and no difference in number of invasive cancers was
found in Destounis [23]. These differences mean that attempts to
combine the results using meta-analysis resulted in signiﬁcant
heterogeneity (I2 ¼ 56%) for the cancer detection rate and for the
invasive cancer detection rate (I2 ¼ 79%). A summary effect was
therefore not calculated. None of the US studies reported a statis-
tically signiﬁcant difference in non-invasive cancer detection rates
between DBT þ FFDM and FFDM alone.
In all of the US studies the proportion of false positives observed
was higher in the FFDM group. However, the magnitude of the
difference in false positives rates varied across the studies, so they
were not combined using meta-analysis. In the large US multi-
centre study (Friedewald 2014 [25e31]), a modest reduction in the
number of false positives was observed: a difference per 1000
screens of 17.4 (95% CI: 15.6 to 19.2) in favour of DBT þ FFDM.
This compared with more substantial reductions in favour of
DBTþ FFDM in Lourenco 2014 of28.7 (95% CI:35.1 to22.2) per
1000 screens and in Destounis 2014 [23] of 74.4 (95% CI: 105.6
to 43.1) per 1000 screens. All differences were highly statistically
signiﬁcant.
In all three studies a higher recall rate was observed in the FFDM
group, but the magnitude of the differences varied across studies.
Reduction in recall in the Friedewald 2014 [25e31] studywas16.2
(95% CI:18.0 to14.5) per 1000 screens, compared to a difference
of 29.4 (95% CI: 36.0 to 22.8) in Lourenco 2014 [24] and a
difference of 72.5 (95% CI: 104.7 to 40.2) in Destounis 2014
[23]. Due to the differences in the recall rate the results of the
studies were not combined using meta-analysis (see Fig. 3).Fig. 3. Differences in false positive rates and rAll of the US studies were based on retrospective analysis. A
paired analysis [31] for a subset of the women participating in
Friedewald 2014 yielded results that were quantitatively similar to
those observed in the parent study [25e31]. Reductions in recall
and false positive rates were observed using DBT þ FFDM:
difference 27.6 (95% CI: 30.8 to 24.5) per 1000 screens
and 29.5 (95% CI: 32.9 to 26.4) per 1000 screens, respectively.
A higher cancer detection rate was also observed using
DBT þ FFDM: difference of 1.9 (95% CI: 1.2 to 2.9) per 1000 screens.
Discussion
Overview of ﬁndings
This systematic review identiﬁed ﬁve studies comparing
DBT þ FFDM with FFDM. Studies varied substantially as they were
performed in different health systems with different screening
paradigms. The ﬁve studies reported the relative cancer detection,
false positive and recall rates for DBT þ FFDM and FFDM. However,
only limited evidence on interval cancers from follow-up is avail-
able at this time, therefore absolute sensitivity and speciﬁcity
cannot be fully evaluated. To reﬂect signiﬁcant differences in
practice, analyses were conducted separately for European and US
studies.
European studies
Two European studies observed higher cancer detection and
invasive cancer detection rates using DBTþ FFDM than FFDM alone.
The differences were statistically signiﬁcant within studies and in
the pooled analysis.
Results for recall and false positive rates vary according to the
double reading algorithm adopted. In STORM [19e22], where
women were recalled if either reader reported a positive ﬁnding,
both false positives and recall were lower using DBT þ FFDM than
using FFDM alone. In OTST [9,17,18] pre-arbitration false positive
rates of individual readers, which are reﬂective of what would
likely be found in a single reader paradigm, were lower for
DBT þ FDDM. Post-arbitration, higher recall and false positive rates
were observed for DBT þ FFDM compared to FFDM. However, DBT
images were available at the arbitration meeting for both the FFDM
and DBTþ FFDM arms. This biases the results in favour of FFDM and
suggests that the recall rate in the FFDM arm was underestimatedecall rates per 1000 screens (US studies).
R. Hodgson et al. / The Breast 27 (2016) 52e6160as an unknown number of cases in this arm may have been dis-
missed during arbitration based on DBT information. Despite this
bias, the higher number of cancers detected with DBT þ FFDM
resulted in the positive predictive value of DBT þ FFDM being
similar to that of FFDM alone. Evidence from the European studies
is currently insufﬁcient to establish the exact impact of DBT on
recall and false positives after consensus reading due to the lack of
prospective blinded consensus reading in both large studies.
US studies
The US study cancer detection results were similar to those of
the European studies, with two of the three US studies demon-
strating an increased cancer detection rate. This included the
largest study in the review, Friedewald 2014 [25e31], which ana-
lysedmore than 450,000 examinations. The observed increase in all
cancers detected and invasive cancers detected was, however,
smaller than that observed in the European studies. This may be
due to the shorter screening interval in the US (1 year) compared to
Europe (2 years), the use of double reading in the European trials, or
the relatively older age of women participating in European
screening programmes. Although one small US study with an un-
paired design observed a lower cancer detection rate using
DBT þ FFDM compared to FFDM, the difference was statistically
insigniﬁcant.
The results of the US studies with regard to recall and false
positive rates were much more consistent and showed sizable and
statistically signiﬁcant reductions in both recalls and false positives.
This is consistent with the results of the European STORM study
[19e22] and the pre-arbitration results of the OTST study which
reﬂect what might be found with a single reader paradigm.
Limitations of the available evidence
While the results of this review suggest DBT is a promising
technology, there are limitations to the available evidence. Data
concerning fully blinded arbitration consensus are still lacking.
Currently, there are only limited data on interval cancers and,
hence, a comparative analysis of programme sensitivity is not
possible. However, higher cancer detection rates with comparable
or improved positive predictive value (PPV) were observed in
studies with fully paired datasets (OTST [9,17,18], STORM [19e22]
and the Rose et al. [31] analysis of the large US multicentre
study). These results demonstrate the better relative sensitivity of
DBT þ FFDM compared to FFDM alone. The current limitation is
that without complete follow-up data, the exact sensitivity and
speciﬁcity of DBT þ FFDM is not known. Studies reporting interval
cancer data are expected to be reporting soon, at which point more
information regarding exact sensitivities and speciﬁcities will be
better understood.
The vast majority of data, including all studies reported in this
review, have been collected using equipment marketed by a single
vendor, Hologic Inc. Studies are ongoing using DBT systems
developed by other manufacturers. The interim results of the
Malm€o Breast Tomosynthesis Screening Trial [32], which used the
equipment of another vendor, was published in May 2015, almost
six months after the deadline of the search criteria for this review
(11/2014). This trial studied single view breast tomosynthesis in
7500 women and reported an increase in cancer detection by 43%
and recall with maintained PPV, with DBT compared to FFDM.
While the results of this study appear comparable to the evidence
included in this review, caution must be used when extrapolating
results from one system to another. As the methods of image
acquisition and reconstruction can differ signiﬁcantly between
systems, clinical performance may also differ.Parallel to this systematic review, Lauby-Secretan [6] published
the Viewpoint of the IARC Working Group on breast cancer
screening, which was based on multiple systematic searches and
which also includes conclusions on the results of DBT. Using
different methodology and a different data base, the conclusions by
Lauby-Secretan and this systematic review are quite similar. This
fact supports the robustness of the results and interpretations. Both
conclusions are, however, limited by the availability of data at the
time of the searches.
Implications for practice
Overall, the evidence suggests that cancer detection rates and
invasive cancer detection rates are higher using DBT þ FFDM than
with FFDM, but non-invasive cancer detection rates are unchanged.
Therefore, the addition of DBT to screening programmes has the
potential to reduce morbidity and mortality associated with breast
cancer by increasing early detection of tumours.
Evidence suggests that recall and false positive rates may be
lower using DBT þ FFDM, especially for single reader paradigms
such as those common in the US. These reductions are particularly
notable given recent emphasis on the potential harms of false
positives and would reduce the number of women experiencing
anxiety and distress caused by false positive examinations [33].
Furthermore, reductions in recalls have the clear added beneﬁt of
decreasing programme costs, particularly in the US where recall
rates are higher than typically reported in Europe. With fewer
women recalled for false positive ﬁndings, fewer diagnostic
mammography, breast ultrasound and biopsies are performed
while cancer detection is maintained.
Deﬁnitive conclusions regarding the impact of DBT on over-
diagnosis cannot be made based on current data. However, over-
diagnosis may be associated with ductal carcinoma in situ (DCIS)
and DBT has not been shown to increase the rate of non-invasive
cancer detection. Current data concerning the incremental inva-
sive cancers detected by DBT do not yet allow ﬁnal conclusions.
However, small and low grade invasive carcinomas can mostly be
treated avoiding aggressive treatments or overtreatment.
The adoption of DBT into screening programmes should also
consider radiation exposure. Acquiring separate DBT and FFDM
acquisitions results in approximately double the dose of a single
FFDM acquisition. Replacing the additional DM acquisition by using
synthesized views from the DBT dataset is now feasible and
therefore reduces this concern. Evidence on the relative perfor-
mance of DBT þ synthesized DM is growing [9,34], but further
research is needed.
Conclusion
Evidence from large scale studies in the US and Europe show
that DBT þ FFDM, compared to FFDM, yields higher invasive cancer
detection rates, increasing the effectiveness of breast cancer
screening. The use of DBT may reduce recalls and thereby reduce
both programme costs and distress caused by a false negative recall.
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